Press releases

2018-09-27 – Press release

Topas Therapeutics to Participate at Upcoming Industry and Scientific Events

Meet with Topas at the following industry events this fall:

  • Sachs 18 th Annual Biotech in Europe Forum
  • BIO-Europe® 2018
  • Meetings around JP Morgan 36 th Annual Global Healthcare Conference
  • Immunology of Diabetes Society Congress 2018
  • Antigen-Specific Immune Tolerance Europe Conference

read more …

2018-04-24 – Press release

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

  • Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies)
  • Initial focus on next generation vector-based therapeutics
  • Boehringer Ingelheim is granted option to in-license several pre-clinical development candidates produced under the collaboration

read more …

2018-01-25 – Press release

Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf

  • Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million.
  • Topas Therapeutics will act as exclusive partner for indication expansions and translation of research results into clinical development.

read more …

2017-11-02 – Press release

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

  • Corporate venture fund invests EUR 4 million (USD 5 million) into Topas
  • Financing to accelerate clinical trials in autoimmune diseases
  • Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas’ Board ofDirectors

read more …

2017-10-26 – Press release

Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer

  • Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering
  • To lead Topas’ clinical development and regulatory affairs

read more …